Modular Medical Announces Successful Validation of Controller Line for Pivot Insulin Delivery System
Key Highlights:Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch.Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch …
Key Highlights:
-
Pivot Controller Line Validated: Manufacturing line has now been validated for human-use production in support of expected Q1 2026 market launch.
-
Pivot will be First Two-Part Tubeless Patch Pump: Pivot, a 3 milliliter removable patch pump, targets the $3 billion dollar market for adult "almost-pumpers" with its affordable, user-friendly, easy-to-learn design.
High-Volume Manufacturing Readiness: Modular Medical's scalable platform positions it to target a significant share of the insulin pump market.
SAN DIEGO, CA / ACCESS Newswire / November 3, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology, today announced the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.
Transforming Diabetes Management - The Pivot is the first tubeless, removable 3 milliliter patch pump designed for adult "almost-pumpers" - individuals with diabetes who hesitate to adopt traditional insulin pumps due to cost, complexity, or design. With its user-friendly interface and affordability, the Pivot expands the insulin pump market to an underserved segment.
"Validating the Pivot controller line further evidences our ability to scale production efficiently, which is a key differentiator in the patch pump space. We remain on track for a Q1 2026 market launch, as we look to introduce our Pivot product to millions of patients who deserve better diabetes management options," said Jeb Besser, CEO of Modular Medical.
Market Impact and Investor Opportunity - The successful validation derisks Modular Medical's path to commercial manufacturing, ensuring reliability and scalability for the launch of the Pivot product. The Company's low-cost, high-volume, manufacturing optimized platform is designed to support the Company's goal to capture significant market share, for the benefit of both patients and investors. Modular Medical's focus on accessibility and innovation positions it as a leader in the rapidly expanding diabetes technology market.

